GlobeNewswire

INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.
24/03/2026
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, March 24, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and [...]
Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of CLD-401 Clinical Trials
24/03/2026
SAN DIEGO, March 24, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today [...]
Leapfrog Bio Appoints Alan Ashworth, Ph.D., FRS, to Chair Company’s Scientific Advisory Board
24/03/2026
-- Dr. Ashworth Brings Decades of Scientific and Clinical Experience Translating Synthetic Lethality Discoveries into Precision Cancer Therapies -- SOUTH SAN FRANCISCO, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- [...]
LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
24/03/2026
Launched VIZZ ® (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in October 2025 and generated net product revenues of $1.6 million in the first quarter of launch On pace for over 45,000 paid [...]
Nautilus Biotechnology to Participate in the Investor Summit Group Virtual Conference
24/03/2026
SEATTLE, March 24, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating [...]
Hyperion DeFi Enters HAUS Agreement with Silhouette
24/03/2026
Latest DeFi Monetization Agreement Generates Scalable Revenues and Ecosystem Rewards in Partnership with Private Trading Infrastructure on Hyperliquid LAGUNA HILLS, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Hyperion [...]
Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
24/03/2026
Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (p< 0.05) Potential 2X treatment benefit compared to 15% and 22% reductions [...]
Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026
24/03/2026
WAYNE, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella” or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]
Bavarian Nordic A/S – Notice Convening Annual General Meeting
24/03/2026
COPENHAGEN, Denmark, 24 March 2026 – Pursuant to Articles 10-14 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the Annual General Meeting to be held on Tuesday, 21 April [...]
Opus Genetics Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
24/03/2026
RESEARCH TRIANGLE PARK, N.C., March 24, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc . (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore [...]
Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
24/03/2026
~ Delivered Record Annual Revenue with Full-Year Net PEDMARK ® Product Sales of $44.6 Million, Representing 50% Year-Over-Year Growth, and Q4 2025 Net Product Sales of $13.8 Million, Representing 75% Growth Over Q4 2024 [...]
American Shared Hospital Services Announces Fourth Quarter and Full Year Financial Results Conference Call
24/03/2026
Call Scheduled for March 31st at 12:00 PM ET SAN FRANCISCO, March 24, 2026 (GLOBE NEWSWIRE) -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of stereotactic radiosurgery [...]
Spectral Medical and Vantive Announce Publication of Complete Results from Spectral’s Tigris Trial in the Lancet Respiratory Medicine
24/03/2026
Tigris publication confirms positive results for primary and key secondary endpoints with 95.3% and 99.4% probability of benefit for PMX at 28-day and 90-day mortality After adjusting for baseline severity, absolute [...]
CAMP4 Appoints Michael MacLean to its Board of Directors
24/03/2026
Appointment enhances strategic and financial leadership as the Company advances CMP-002 toward a planned first-in-human Phase 1/2 clinical trial for SYNGAP1-related disorder CAMBRIDGE, Mass., March 24, 2026 (GLOBE [...]
Achieve Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
24/03/2026
Achieve also Announces Partnership with U.S.-based Adare Pharma Solutions for Cytisinicline Manufacturing Conference Call Scheduled for 8:30 AM EDT Today, March 24, 2026 SEATTLE and VANCOUVER, British Columbia, March 24 [...]
Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering
24/03/2026
ISELIN, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, [...]
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress
24/03/2026
Key highlights for the first full year of operation under the new management team include: A year-over-year reduction in operating expenses with $7.8 Million cash on hand at year end. With ongoing revenue from [...]
Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting
24/03/2026
FDA encourages the Company to submit comprehensive data from sunRIZE and the ongoing open-label extension to inform next steps for the program REDWOOD CITY, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. ( [...]
Sanara MedTech Inc. Reports Fourth Quarter (Unaudited) and Full Year 2025 Financial Results; Reaffirmed Full Year 2026 Financial Guidance
24/03/2026
FORT WORTH, TX, March 24, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum